Join us for a panel discussion which will attempt to move beyond unsuccessful debates that pit innovation against equitable access to medicine. In doing so, panellists will draw on their own experiences in relation to re-thinking vaccine creation, production, and distribution. They will also consider what is needed to revision intellectual property to support the creation and delivery of new therapies, both in times of crisis and times of calm.